Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDORELA neoadjuvant nivolumab with or without relatlimab for resectable muscle-invasive bladder cancer
NL-OMON59525Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing nivolumab with nivolumab + relatlimab (2 arms). Primary endpoint: Pathological complete response. Started Feb 2024; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON59525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59525.